Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents

Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents

Abstract Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all NHLs and characterized by overexpression of cyclin D1. The last decade has seen the development of many novel treatment approaches in MCL, most notably the class of Bruton's tyrosine kinase inhibitors...

Full description

Bibliographic Details
Main Authors: Neeraj Jain, Mukesh Mamgain, Sayan Mullick Chowdhury, Udita Jindal, Isha Sharma, Lalit Sehgal, Narendranath Epperla
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Journal of Hematology & Oncology
Subjects:
BTK inhibitor resistance
Mantle cell lymphoma
CAR T cell therapies
Bispecific antibodies
Antibody–drug conjugates
Online Access:https://doi.org/10.1186/s13045-023-01496-4

Internet

https://doi.org/10.1186/s13045-023-01496-4

Similar Items